Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
Sign Up to like & getrecommendations! Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s382722
Abstract: Abstract Several selective mesenchymal–epithelial transition (MET) inhibitors have recently demonstrated favorable systemic efficacy in MET exon 14 skipping mutation-positive non-small cell lung cancer. However, there are limited data on their efficacy against central nervous system… read more here.
Keywords: skipping mutation; lung; met exon; mutation ... See more keywords
Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_591_18
Abstract: Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare histologic subtype of nonsmall cell lung cancer with limited targeted treatment options. In this study, we aimed to investigate the prevalence of MET ex14 skipping mutation in… read more here.
Keywords: prevalence met; skipping mutation; common targetable; met ex14 ... See more keywords